Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Eigentler

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyLisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyLars Hofmann, Andrea Forschner, Carmen Loquai, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
Journal for Immunotherapy of Cancer|January 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanomaNicola Herold, Jonas Bochem, Johanna Leyens, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingDanny Rischin, Michael R Migden, Annette M Lim, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 16, 2020
Ulrike Leiter, Markus V Heppt, Theresa Steeb, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 5, 2020
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicatorsMarkus V Heppt, Ulrike Leiter, Theresa Steeb, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 5, 2020
Markus V Heppt, Ulrike Leiter, Theresa Steeb, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 5, 2020
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational diseaseUlrike Leiter, Markus V Heppt, Theresa Steeb, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitorsRafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyLisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyLars Hofmann, Andrea Forschner, Carmen Loquai, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
Journal for Immunotherapy of Cancer|January 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanomaNicola Herold, Jonas Bochem, Johanna Leyens, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingDanny Rischin, Michael R Migden, Annette M Lim, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 16, 2020
Ulrike Leiter, Markus V Heppt, Theresa Steeb, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 5, 2020
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicatorsMarkus V Heppt, Ulrike Leiter, Theresa Steeb, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 5, 2020
Markus V Heppt, Ulrike Leiter, Theresa Steeb, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 5, 2020
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational diseaseUlrike Leiter, Markus V Heppt, Theresa Steeb, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitorsRafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
Pageof 13